Clinical Trial: Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

U.S., June 28 -- ClinicalTrials.gov registry received information related to the study (NCT07040319) titled 'Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV' on June 13.

Brief Summary: This is a Phase I/II, multi-site, open-label, single arm study to describe the pharmacokinetics (PK) and safety of glecaprevir/pibrentasvir (GLE/PIB) initiated during pregnancy in women with hepatitis C virus (HCV) infection (acute or chronic) with or without HIV and to evaluate safety for their infants through 10 weeks postpartum.

Study Start Date: Nov. 28, 2025

Study Type: INTERVENTIONAL

Condition: Hepatitis C

Intervention: DRUG: Glecaprevir/pibrentasvir

100 m...